More information from the recent report :-
"During the quarter, the Company had cash flows from operations of positive $1.32 million, resulting in a cash balance of $6.8 million as at 31 December 2019. This includes the receipt of $3.8 million form the R&D Tax Incentive refund. As previously announced, OncoSil continues to operate under a revised business plan as it awaits the outcome of the CE Mark decision. The Company has continued with these measures with the aim of maximising long-term shareholder value and strengthening its cashflow position. "
More information from the recent report :- "During the quarter,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.035(3.48%) |
Mkt cap ! $13.79M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 97.0¢ | $66.41K | 66.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3907 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 3000 | 1 |
View Market Depth
| Last trade - 15.47pm 23/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |